Node Not Found: --Node Not Found: -- Meetings - The ASCO Post

IASLC 16th World Conference on Lung Cancer

lung cancer

Ramaswamy Govindan, MD: Roundup of Lung Cancer Findings

Ramaswamy Govindan, MD, of Washington University, summarizes three important papers: ROVA-T in relapsed and refractory small cell lung cancer, genomic characterization of large-cell neuroendocrine tum...

lung cancer

Guneet Walia, PhD, on Central Issues in Lung Cancer Care

Guneet Walia, PhD, of the Lung Cancer Foundation, summarizes some key presentations: bridging the quality chasm, patients’ attitudes and physicians’ perceptions on maintenance therapy, and patient adv...

lung cancer

Jennifer King, PhD: Scientific Perspectives From the Lung Cancer Alliance

Jennifer King, PhD, of the Lung Cancer Alliance, gives her perspective on major themes of this year’s meeting: the stigma of lung cancer, the changing face of who is affected, early detection, and adv...

lung cancer

Everett E. Vokes, MD, on Controversies in Stage IIIA Disease

Everett E. Vokes, MD, of the University of Chicago, summarizes expert views on treating stage IIIA disease: decision-making in selecting patients for surgery; multiple-modality choices; and using indu...

lung cancer

Naiyer A. Rizvi, MD, on Immune Checkpoint Inhibitors

Naiyer A. Rizvi, MD, of Columbia University, offers an update on immune checkpoint inhibitors in non–small cell lung cancer: what’s new and what’s next.

lung cancer

Nagashree Seetharamu, MD, on Anti-Glycan Antibody Profiling in De Novo Stage IV Non Small Cell Lung Cancer

Nagashree Seetharamu, MD, of the North Shore LIJ Health System, discusses serum AGA-signatures that may provide a minimally invasive test for early detection of lung cancer risk (Abstract P3.04-085).

lung cancer

William D. Travis, MD, on Pathology and Genetics of Lung Tumors: 2015 WHO Classification

William D. Travis, MD, of Memorial Sloan Kettering Cancer Center, gives an update on the WHO classification, which is crucial for optimal personalized treatment of lung cancer patients (Abstract PLEN0...

lung cancer

Fred R. Hirsch, MD, PhD, and Paul A. Bunn, Jr., MD, on the Highlights of the World Conference on Lung Cancer

Fred R. Hirsch, MD, PhD, of the University of Colorado Health Science Center, and Paul A. Bunn, Jr, MD, of the University of Colorado Cancer Center, give their views on the goals and important present...

lung cancer

Karen Kelly, MD, on PD-1 Axis Inhibition and the Treatment of Advanced Disease

Karen Kelly, MD, of the University of California, Davis, summarizes three important papers on NSCLC: expression as a predictive biomarker; pembrolizumab, immune-mediated adverse events, and corticoste...

lung cancer

Philip Bonomi, MD, on SBRT and Surgery for Localized Disease

Philip Bonomi, MD, of Rush Medical College, summarizes a debate on two important issues: choosing between surgery and stereotactic body radiation therapy (SBRT) in operable NSCLC, and whether or not t...

lung cancer
symptom management

Philip Bonomi, MD, on Results of the Romana 1 and Romana 2 Trials

Philip Bonomi, MD, of Rush Medical College, summarizes the findings on anamorelin and its use in advanced NSCLC for improvement in anorexia/cachexia symptoms (Abstracts ORAL 29.01, ORAL 29.02).

lung cancer

Ugo Pastorino, MD, on Reducing Lung Cancer Mortality

Ugo Pastorino, MD, of the Istituto Nazionale dei Tumori Foundation, discusses his study, which showed that stopping smoking before or during low-dose computed tomography screening reduced overall mort...

lung cancer

Pasi A. Jänne, MD, PhD, on Integration of Next Generation Data Into the Clinic

Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, summarizes a workshop he conducted on the state of the art in next-generation sequencing of lung cancer (Abstract WS 01.07).

lung cancer

James R. Jett, MD, on Screening With Early CDT and CT

James R. Jett, MD, of National Jewish Health, discusses his study of the early CDT-Lung biomarker. His hypothesis: When used in combination with low-dose CT in screening of a high-risk population, thi...

lung cancer

Vassiliki Papadimitrakopoulou, MD, on The Lung MAP Clinical Trial

Vassiliki Papadimitrakopoulou, MD, of MD Anderson Cancer Center, discusses the ways in which patients, investigators, and pharmaceutical companies are working together to accelerate research and acces...

lung cancer

James L. Mulshine, MD, on Lung Cancer Screening in the United States: Can It Happen?

James L. Mulshine, MD, of Rush University Medical Center, discusses the profound challenges of implementing national CT screening to ensure delivery of high-quality, best-practice early lung cancer de...

lung cancer

Christine D. Berg, MD, on Screening for Lung Cancer in Those at High Risk

Christine D. Berg, MD, of Johns Hopkins Medicine, discusses how increased insurance coverage should dramatically increase lung cancer screening. If done correctly—which will be a challenge—screening w...

lung cancer

Alice T. Shaw, MD, PhD, on ALK, Crizotinib, and Alectinib

Alice T. Shaw, MD, PhD, of Massachusetts General Hospital, summarizes efficacy and safety data from studies on crizotinib, brigatinib, and alectinib for ALK-positive non–small cell lung cancer (ORAL 3...

lung cancer

Heather A. Wakelee, MD, on Results of the E1505 Clinical Trial

Heather A. Wakelee, MD, of Stanford University discusses the study that explored the question of whether adding bevacizumab to adjuvant chemotherapy is beneficial in the setting of resected non–small ...

lung cancer

Tony Mok, MD, and Fred R. Hirsch, MD, PhD: Summary of the IASLC Presidential Symposium

Tony Mok, MD, of The Chinese University of Hong Kong, and Fred R. Hirsch, MD, PhD, of University of Colorado Health Science Center discuss the highlights of the featured plenary session, which include...

lung cancer

Roy S. Herbst, MD, PhD, on Results From SWOG S0819

Roy S. Herbst, MD, PhD, of the Smilow Cancer Hospital at Yale Cancer Center, discusses his findings of a phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab with or ...

lung cancer

Silvia Novello, MD, PhD: Lung Cancer Is a Women's Disease Too

Silvia Novello, MD, PhD, of the University of Turin, discusses a much-neglected aspect of lung cancer: It is not just the province of men; women are affected in great numbers as well.

lung cancer

Barbara J. Gitlitz, MD: Genomics of Young Lung Cancer Study

Barbara J. Gitlitz, MD, of USC/Norris Cancer Center, discusses the first prospective study on the genomic drivers and demographics of lung cancer in patients under 40 who took part in the study remote...

lung cancer

Howard Jack West, MD, on New Kinase Targets for Treating Advanced NSCLC

Howard Jack West, MD, of the Swedish Cancer Institute, summarizes three important papers: anlotinib as third-line treatment for refractory advanced non–small cell lung cancer; the EGFR exon 20 mutatio...

lung cancer

Eric Lim, MD, on Increasing Incidence of Non-Smoking Lung Cancer

Eric Lim, MD, of the Royal Brompton and Harefield NHS Trust, discusses his findings on the nonspecific symptoms of never-smokers, which suggests that imaging could play a more important role in diagno...

lung cancer

Lorraine Cheryl Pelosof, MD, PhD, on Never-Smokers in NSCLC

Lorraine Cheryl Pelosof, MD, PhD, of UT Southwestern Medical Center, discusses her study findings, which demonstrate an increasing proportion of never-smokers among patients with non–small cell lung c...

lung cancer

ALK Rearrangements Common in Young Patients With Lung Cancer

Two investigative groups have reported interesting observations about genomic alterations in the tumors of young patients with lung cancer. Notably, ALK rearrangement was the most common driver mutati...

lung cancer

Bevacizumab Plus Chemotherapy Fails to Prolong Survival in Early-Stage Lung Cancer

Overall survival in patients with surgically resected early-stage non–small cell lung cancer (NSCLC) did not improve with the addition of bevacizumab (Avastin) to chemotherapy, according to the findin...

lung cancer

Bevacizumab Plus Standard Chemotherapy Improves Survival in Mesothelioma

The standard of care for malignant pleural mesothelioma may be poised for change, judging by results from a study by the French Cooperative Thoracic Intergroup. The addition of bevacizumab (Avastin) i...

Lung Cancer

First-Line Nivolumab/Ipilimumab Combination in Non–Small Cell Lung Cancer Shown to Be Tolerable

For advanced non–small cell lung cancer (NSCLC), first-line treatment with combined immune checkpoint blockade—in novel doses and schedules—was associated with deep and durable responses, encouraging ...

Lung Cancer Rates Doubling Among Nonsmokers

Lung cancer is becoming an equal-opportunity malignancy—with rates rising among never-smokers, especially females, according to studies presented at the 16th World Conference on Lung Cancer in Denver....

lung cancer

AZD9291 Updates Encouraging for Treatment-Resistant NSCLC

At the 16th World Conference on Lung Cancer, several studies showed consistent activity with the investigational third-generation inhibitor AZD9291 in patients with advanced non–small cell lung cancer...

lung cancer

Nivolumab in Lung Cancer Supported by Updated Trial Data

For the treatment of advanced squamous non–small cell lung cancer (NSCLC), the programmed cell death protein 1 (PD-1) antibody nivolumab (Opdivo) continues to show results in key trials that now repor...

lung cancer

EGFR Gene Copy Number as Biomarker for Antibody Treatment in Squamous Cell NSCLC

Two studies presented at the 16th World Conference on Lung Cancer suggest that high expression of the epidermal growth factor receptor (EGFR), or gene copy number, may indicate potential benefit from ...

Delays in Drug Approval Are Deadly, Highlighting the Need for Improved Regulatory Efficiency

Researchers have determined just how many lives are lost when effective investigational drugs are not approved in a timely manner. These delays in the process of anticancer drug approvals result in th...

Lung Cancer

Smoking Cessation Reduces Mortality in Lung Cancer Screening Population

Data from an analysis of lung cancer screening programs in Italy add further evidence that smoking cessation reduces mortality. Heavy smokers screened by low-dose computed tomography (CT) who stopped ...

Advertisement

Advertisement



Advertisement

click me